● British start-up Clerkenwell Health, Europe’s first commercial psychedelic clinical trials facility, and brain wellness and analytics company MYndspan, are partnering to advance the application of psychedelics in medicine ● Psychedelics researchers running trials at Clerkenwell Health’s new London site will have access to MYndspan’s non-invasive brain scanning technology ● This first-of-its-kind…

Source

Previous articleMIND CURE CLOSES PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT
Next articleTerran Biosciences announces publication of four PCT patent applications covering breakthroughs in novel empathogens, including improved versions of methylone, ethylone, MDEA, MDAI, and MBDB